Please assess the completion status of the following clinical trial:

Trial Title: 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria and have a clinical diagnosis of probable AD according to NINCDS/ADRDA criteria~* MMSE score of ≥ 10 and ≤ 26~* The treatment naïve patient and the one who have stopped the donepezil, galantamine, huperzine A, or memantine at least 2 weeks~* Be in stable medical condition~* Have signed off informed consent form by patients or his/her legal guardian~Key Exclusion Criteria:~* Severe AD~* Patients with a history of cerebrovascular disease, Active or uncontrolled epilepsy, Active hypothyroidism, asthma, CNS infection, other Neurodegenerative disorders, an advanced, severe, progressive, or unstable medical condition~* Attending other clinical trials or taking other clinical trial drugs~* A score of \> 4 on the Modified Hachinski Ischemic Scale (MHIS);~* Patients who is using any AChEI or memantine

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ENA713 (Type: EXPERIMENTAL): Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).